CBD Life Sciences Inc. (OTCMKTS:CBDL – Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 399,666 shares, a decrease of 93.6% from the April 15th total of 6,209,240 shares. Based on an average trading volume of 109,899,084 shares, the short-interest ratio is currently 0.0 days.
CBD Life Sciences Stock Performance
CBDL opened at $0.00 on Wednesday. CBD Life Sciences has a 52-week low of $0.00 and a 52-week high of $0.00.
CBD Life Sciences Company Profile
CBD Life Sciences, Inc is a U.S.-based company focused on developing and commercializing cannabinoid‐enhanced products for the wellness and consumer healthcare markets. The company’s core strategy centers on leveraging plant-derived phytocannabinoids, along with complementary natural ingredients, to formulate a range of topical and ingestible offerings. CBD Life Sciences operates under an emerging‐brand model, seeking to position its products at the intersection of pharmaceutical‐grade quality and mainstream consumer appeal.
The company’s product portfolio includes broad‐spectrum hemp-derived topical creams, gels and balms designed for localized relief, as well as oral formulations such as capsules, tinctures and soft gels aimed at general wellness support.
Featured Articles
- Five stocks we like better than CBD Life Sciences
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
Receive News & Ratings for CBD Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CBD Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
